285 related articles for article (PubMed ID: 26356822)
1. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
Wang Y; Wang Y; Wang N; You L; Long F; Shao C; Wang Y; Wu J
Oncol Rep; 2019 Oct; 42(4):1467-1474. PubMed ID: 31322269
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of poly(ADP-ribose) recognition by the multizinc binding domain of checkpoint with forkhead-associated and RING Domains (CHFR).
Oberoi J; Richards MW; Crumpler S; Brown N; Blagg J; Bayliss R
J Biol Chem; 2010 Dec; 285(50):39348-58. PubMed ID: 20880844
[TBL] [Abstract][Full Text] [Related]
4. Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors.
Ogi K; Toyota M; Mita H; Satoh A; Kashima L; Sasaki Y; Suzuki H; Akino K; Nishikawa N; Noguchi M; Shinomura Y; Imai K; Hiratsuka H; Tokino T
Cancer Biol Ther; 2005 Jul; 4(7):773-80. PubMed ID: 16123600
[TBL] [Abstract][Full Text] [Related]
5. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
Pillai RN; Brodie SA; Sica GL; Shaojin Y; Li G; Nickleach DC; Yuan L; Varma VA; Bonta D; Herman JG; Brock MV; Ribeiro MJ; Ramalingam SS; Owonikoko TK; Khuri FR; Brandes JC
Clin Cancer Res; 2013 Mar; 19(6):1603-11. PubMed ID: 23386692
[TBL] [Abstract][Full Text] [Related]
6. CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation.
Kashima L; Idogawa M; Mita H; Shitashige M; Yamada T; Ogi K; Suzuki H; Toyota M; Ariga H; Sasaki Y; Tokino T
J Biol Chem; 2012 Apr; 287(16):12975-84. PubMed ID: 22337872
[TBL] [Abstract][Full Text] [Related]
7. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin resistance associated with PARP hyperactivation.
Michels J; Vitale I; Galluzzi L; Adam J; Olaussen KA; Kepp O; Senovilla L; Talhaoui I; Guegan J; Enot DP; Talbot M; Robin A; Girard P; Oréar C; Lissa D; Sukkurwala AQ; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Dessen P; Saparbaev M; Soria JC; Castedo M; Kroemer G
Cancer Res; 2013 Apr; 73(7):2271-80. PubMed ID: 23554447
[TBL] [Abstract][Full Text] [Related]
9. Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
Takeshita M; Koga T; Takayama K; Yano T; Maehara Y; Nakanishi Y; Sueishi K
Cancer Biol Ther; 2010 Nov; 10(9):933-41. PubMed ID: 20855974
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
[TBL] [Abstract][Full Text] [Related]
11. Connections between CHFR, the cell cycle, and chemosensitivity: Are they critical in cancer?
Keller JA; Erson-Bensan AE; Petty EM
Cancer Biol Ther; 2010 Nov; 10(9):942-4. PubMed ID: 21057211
[No Abstract] [Full Text] [Related]
12. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
13. USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase.
Giovinazzi S; Morozov VM; Summers MK; Reinhold WC; Ishov AM
Cell Death Differ; 2013 May; 20(5):721-31. PubMed ID: 23348568
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J
Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
Satoh A; Toyota M; Itoh F; Sasaki Y; Suzuki H; Ogi K; Kikuchi T; Mita H; Yamashita T; Kojima T; Kusano M; Fujita M; Hosokawa M; Endo T; Tokino T; Imai K
Cancer Res; 2003 Dec; 63(24):8606-13. PubMed ID: 14695171
[TBL] [Abstract][Full Text] [Related]
16. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins.
Ahel I; Ahel D; Matsusaka T; Clark AJ; Pines J; Boulton SJ; West SC
Nature; 2008 Jan; 451(7174):81-5. PubMed ID: 18172500
[TBL] [Abstract][Full Text] [Related]
18. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
[TBL] [Abstract][Full Text] [Related]
19. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
Pelosof L; Yerram SR; Ahuja N; Delmas A; Danilova L; Herman JG; Azad NS
Int J Cancer; 2014 Feb; 134(3):596-605. PubMed ID: 23873170
[TBL] [Abstract][Full Text] [Related]
20. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
Zhang L; Li DQ
Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]